Baidu
map

Obstet Gynecol:孕期抗精神病药物暴露增加妊娠不良结局

2015-05-05 MedSci MedSci原创

越来越多的生育年龄的女性使用抗精神病药物。这些药物在孕期的安全性尚不明确。因此Coughlin CG等人对在怀孕期间暴露于抗精神病药物事件进行了系统回顾和荟萃分析以评估不良产科和新生儿结果。该研究共纳入了十三项队列研究,其中包括6289抗精神病药物暴孕妇和1618039名对照组。研究结果表明,抗精神病药物暴露会导致以下不良结局风险增加:主要畸形(ARD 0.03,

越来越多的生育年龄的女性使用抗精神病药物。这些药物在孕期的安全性尚不明确。因此Coughlin CG等人对在怀孕期间暴露于抗精神病药物事件进行了系统回顾和荟萃分析以评估不良产科和新生儿结果。该研究共纳入了十三项队列研究,其中包括6289抗精神病药物暴孕妇和1618039名对照组。

研究结果表明,抗精神病药物暴露会导致以下不良结局风险增加:主要畸形(ARD 0.03, 95% CI 0.00-0.05, P=.04, Z=2.06);心脏缺陷 (ARD 0.01, 95% CI 0.00-0.01, P<.001, Z=3.44);早产 (ARD 0.05, 95% CI 0.03-0.08, P<.001, Z=4.10);小于胎龄儿 (ARD 0.05, 95% CI 0.02-0.09, P=.006, Z=2.74);选择性终止妊娠(ARD 0.09, 95% CI 0.05-0.13, P<.001, Z=4.69);出生体重下降(weighted mean difference -57.89 g, 95% CI -103.69 to -12.10 g, P=.01)。在常用/典型的抗精神病药物(OR 1.55, 95% CI 1.21-1.99, P=.006)和其他抗精神病药物(OR 1.39, 95% CI 0.66-2.93, P=.38)间主要畸形的风险没有显著差异(test for subgroup differences: χ²=0.07, degrees of freedom=1, P=0.79)。暴露于抗精神病药物不会导致下列不良结局风险增加:大于胎龄儿、死胎死产、自发性流产。虽然怀孕期间接触抗精神病的会增加不良产科和新生儿结局风险,但,这种关联并不一定意味着就是因果关系。有限的研究和有限的校正都可能对该研究结果的分析造成混杂影响。

研究结果表明,不管抗精神病药物与不良产科和新生儿结局间是否有因果关系,但是要求抗精神病治疗的妇女在怀孕期间出现在不良生育结果的风险仍会更高,不过密切监测和最小化怀孕期间的其他潜在风险因素能让妊娠受益,得到更好的结局。

原始出处:

Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015. 125(5): 1224-35.

本文系Medsci原创编译整理!转载需要先获得授权,并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958106, encodeId=598719581064a, content=<a href='/topic/show?id=4f2f8e771bc' target=_blank style='color:#2F92EE;'>#药物暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87771, encryptionId=4f2f8e771bc, topicName=药物暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Feb 03 02:11:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043848, encodeId=f6bf204384853, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 06 17:11:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011186, encodeId=6f8520111864c, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Feb 18 18:11:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513054, encodeId=517115130543e, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu May 07 09:11:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22828, encodeId=0c7422828c7, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 06 22:16:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22669, encodeId=3fa42266975, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Tue May 05 22:49:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958106, encodeId=598719581064a, content=<a href='/topic/show?id=4f2f8e771bc' target=_blank style='color:#2F92EE;'>#药物暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87771, encryptionId=4f2f8e771bc, topicName=药物暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Feb 03 02:11:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043848, encodeId=f6bf204384853, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 06 17:11:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011186, encodeId=6f8520111864c, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Feb 18 18:11:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513054, encodeId=517115130543e, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu May 07 09:11:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22828, encodeId=0c7422828c7, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 06 22:16:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22669, encodeId=3fa42266975, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Tue May 05 22:49:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958106, encodeId=598719581064a, content=<a href='/topic/show?id=4f2f8e771bc' target=_blank style='color:#2F92EE;'>#药物暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87771, encryptionId=4f2f8e771bc, topicName=药物暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Feb 03 02:11:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043848, encodeId=f6bf204384853, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 06 17:11:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011186, encodeId=6f8520111864c, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Feb 18 18:11:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513054, encodeId=517115130543e, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu May 07 09:11:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22828, encodeId=0c7422828c7, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 06 22:16:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22669, encodeId=3fa42266975, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Tue May 05 22:49:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
    2016-02-18 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958106, encodeId=598719581064a, content=<a href='/topic/show?id=4f2f8e771bc' target=_blank style='color:#2F92EE;'>#药物暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87771, encryptionId=4f2f8e771bc, topicName=药物暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Feb 03 02:11:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043848, encodeId=f6bf204384853, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 06 17:11:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011186, encodeId=6f8520111864c, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Feb 18 18:11:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513054, encodeId=517115130543e, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu May 07 09:11:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22828, encodeId=0c7422828c7, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 06 22:16:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22669, encodeId=3fa42266975, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Tue May 05 22:49:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958106, encodeId=598719581064a, content=<a href='/topic/show?id=4f2f8e771bc' target=_blank style='color:#2F92EE;'>#药物暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87771, encryptionId=4f2f8e771bc, topicName=药物暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Feb 03 02:11:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043848, encodeId=f6bf204384853, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 06 17:11:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011186, encodeId=6f8520111864c, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Feb 18 18:11:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513054, encodeId=517115130543e, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu May 07 09:11:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22828, encodeId=0c7422828c7, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 06 22:16:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22669, encodeId=3fa42266975, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Tue May 05 22:49:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
    2015-05-06 huaxipanxing

    了解

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1958106, encodeId=598719581064a, content=<a href='/topic/show?id=4f2f8e771bc' target=_blank style='color:#2F92EE;'>#药物暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87771, encryptionId=4f2f8e771bc, topicName=药物暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Wed Feb 03 02:11:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043848, encodeId=f6bf204384853, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 06 17:11:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011186, encodeId=6f8520111864c, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Feb 18 18:11:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513054, encodeId=517115130543e, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu May 07 09:11:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22828, encodeId=0c7422828c7, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 06 22:16:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22669, encodeId=3fa42266975, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=230, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Tue May 05 22:49:00 CST 2015, time=2015-05-05, status=1, ipAttribution=)]
    2015-05-05 zhouanxiu

    了解

    0

相关资讯

J Watch评价:褪黑素用于药物诱导代谢综合征

在一项早期研究中,褪黑素似乎可减轻非典型抗精神病药物应用期间出现的体重增长。 非典型抗精神病药物经常导致体重增长及其他不良代谢后果。接受行业资助的研究者们基于动物研究结果,提出了褪黑素可能有助于减轻上述影响的假设。 在晚上8时,随机给予50例服用氯氮平、奥氮平、利培酮或喹硫平<3个月的受试者为期8周的缓释型褪黑素(5 mg)或安慰剂治疗。在完成研究的24例精神分裂症和2

J Clin Psychiatry:常见精神病药物对新生儿的影响

因为涉及伦理等问题,临床上对于孕期服用精神病药物的有效性和安全性的研究几乎没有,因为研究证据的不足,治疗精神疾患的药物对于胚胎的毒性一直不明确,当孕妇伴有严重精神病的时候,用药对孕妇好,但是对胎儿呢?结果是未知的,所以究竟用不用药,如何用药,这个问题一直困扰着医患双方,使其在临床决策时陷入两难。

铜陵精神病专家余翔闹市遇刺身亡 募捐活动正在进行中

1月4日晚,铜陵闹市区发生一起凶杀案,一名和友人在体育馆散步的精神病专家被人持利器连捅数刀身亡,凶手逃脱。事后有医疗同行发帖爆料,凶手系被害医生的病人,对其早就心生不满。但这一情况记者询问铜陵警方未得到证实。目前,铜陵警方还在寻找嫌疑人,全力侦破该案。专家散步时遇刺身亡今年48岁的余翔是铜陵市第三人民医院残疾人托养中心主任,心理学专家。据了解,铜陵市第三人民医院是二级精神疾病防治专科医院。 1

Lancet Psychiatry:部分首发精神病是由于大麻的使用

药物使用所引起副作用的风险主要是基于药物使用的频率和所用药物的效价。Lancet Psychiatry报道了英国研究人员对高效价大麻的使用频率如何影响大麻和精神疾病之间的联系的病例对照研究。 研究人员对数据应用逻辑回归模型进行分析。这些数据来自南伦敦和莫兹利NHS基金会的患有首发精神病的18-65岁病人和从南伦敦相同的地区招募的参与者。通过这些数据估计使用频率的作用和大麻的使用在精神

JAMA:儿童抗精神病药物处方授权政策前的检查

根据研究3月3日发表在JAMA上的一项研究,随着对抗精神病药物对儿童不适宜处方关注的,美国31个州已对非典型抗精神病药物的处方实行事先批准的政策,这主要发生在过去的5年,大多数州已经施行了7岁以下儿童的用药政策。 在过去的二十年中,对青少年的抗精神病药物,几乎只包括非典型抗精神病药物,这已经从1993-1998年之间的0.16%增长到2005-2009年到医生就诊的1.07%。抗精神病药物在医疗

Pers Individ Dif:爱自拍男性多自恋且有精神病倾向?

台媒称,美国一项最新研究指出,热衷自拍并经常将照片上传到社交网站的男性,有自恋倾向,并可能有精神问题。 据台湾“中央社”29日援引英媒报道,美国俄亥俄州立大学(The Ohio State University)研究人员对800名年龄在18到40岁的男性进行调查,询问他们自拍次数,张贴个人照片频率,在张贴前是否修改照片,同时请受访者填写有关反社会行为

Baidu
map
Baidu
map
Baidu
map